Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy

A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy

To assess the efficacy and safety of Etanercept in patients with spondylarthropathy and refractory heel enthesitis.

Inclusion criteria

• Spondylarthropathy
• Heel enthesitis refractory to standard treatment
• Between 18 and 70 years of age
• The patient global assessment of the disease activity (measured by a 100 mm VAS) must be >40 in the last 48 hours

Exclusion criteria

• Use of > 1 local steroid injection within 2 weeks of screening
• Prior exposure to any TNF-inhibitor, including etanercept
• Dose of NSAIDs changed within two weeks of study drug evaluation